This Biotech Stock Is Soaring 132% After Key FDA Panel Vote on Skin Cancer Treatment

Impact · against what's priced in

Replimune's stock price is reacting to a material increase in the probability of drug approval following a positive FDA advisory committee vote. This clinical validation serves as a primary catalyst for future commercial revenue expectations.

REPL+0.80

No priced-in read yet

In context

The FDA advisory committee's vote that the skin cancer treatment study is 'clinically meaningful' significantly increases the likelihood of regulatory approval and commercialization.

Read from the article alone

• healthcare
• biotech
• REPL
• clinical trial
• fda
• skin cancer

Search tags